An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism - The German perspective

Surgery

Volumn 148, Issue 6, 2010, Pages 1091-1099

  Schneider, Ralph ^a   Kolios, Georgios ^b   Koch, Benjamin M ^a   Fernández, Emilio Domínguez ^c   Bartsch, Detlef K ^a   Schlosser, Katja ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c Department of General Visceral and Vascular Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; PARICALCITOL;

AMBULATORY CARE; ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; HEALTH CARE FINANCING; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PARATHYROIDECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; SUPPLEMENTATION;

BONE DENSITY CONSERVATION AGENTS; COST CONTROL; COSTS AND COST ANALYSIS; ERGOCALCIFEROLS; GERMANY; HUMANS; HYPERPARATHYROIDISM, SECONDARY; NAPHTHALENES; PARATHYROIDECTOMY;

EID: 78649950675     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2010.09.009     Document Type: Article

References (24)

1. G. Schlieper, and J. Floege Calcimimetics in CKD-results from recent clinical studies Pediatr Nephrol 23 2008 1721 1728
2. E. Lewin, W. Wang, and K. Olgaard Reversibility of experimental secondary hyperparathyroidism Kidney Int 52 1997 1232 1241
3. K. Schlosser, J.A. Veit, S. Witte, E.D. Fernández, N. Victor, and H.P. Knaebel Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial Trials 8 2007 22
4. A.J. Felsenfeld Considerations for the treatment of secondary hyperparathyroidism in renal failure J Am Soc Nephrol 8 1997 993 1004
5. A.J. Brown, and E. Slatopolsky Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease Nat Clin Pract Endocrinol Metab 3 2007 134 144
6. P. Evenepoel Calcimimetics in chronic kidney disease: evidence, opportunities and challenges Kidney Int 74 2008 265 275
7. J. Cunningham, M. Danese, K. Olson, P. Klassen, and G.M. Chertow Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 2005 1793 1800
8. Y. Tominaga, S. Matsuoka, and N. Uno Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis World J Surg 33 2009 2335 2342
9. J. Coresh, B.C. Astor, T. Greene, G. Eknoyan, and A.S. Levey Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 2003 1 12
10. M.S. Joy, P.C. Karagiannis, and F.W. Peyerl Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment J Manag Care Pharm 13 2007 397 411
11. J. Portolés, A. Tato, P. López-Sánchez, E. Gruss, F. Cava, and A. Ortigosa [Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment, a one-year, prospective study] Nefrologia 28 2008 419 424
12. L.A. Szczech The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials Kidney Int Suppl 2004 S46 S48
13. G.A. Block The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease Kidney Int Suppl 2003 S131 S136
14. E.F. Nemeth, M.E. Steffey, and J. Fox The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism Pediatr Nephrol 10 1996 275 279
15. J. Lindberg, K.J. Martin, E.A. González, S.R. Acchiardo, J.R. Valdin, and C. Soltanek A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease Clin Nephrol 56 2001 315 323
16. F. Llach, and M. Yudd Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism Am J Kidney Dis 38 2001 S45 S50
17. E. Lazar, K. Hebert, T. Poma, and N. Stankus Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism Am J Nephrol 27 2007 274 278
18. M. Fukagawa, and M. Taniguchi Can calcimimetics inhibit nodular hyperplasia of parathyroid glands? Nephrol Dial Transplant 23 2008 407 408
19. P. Ureña, S.H. Jacobson, E. Zitt, M. Vervloet, F. Malberti, and N. Ashman Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice-the ECHO observational study Nephrol Dial Transplant 24 2009 2852 2859
20. T. Hirai, A. Nakashima, N. Takasugi, and N. Yorioka Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size Nephron Clin Pract 114 2010 c187 c193
21. T. Kakuta, R. Tanaka, G. Kanai, A. Sawaya, T. Hirukawa, and A. Sato Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism? Ther Apher Dial 13 Suppl 1 2009 S20 S27
22. National Institute for Health and Clinical Excellence. Understanding NICE guidance. Information for people who use NHS services Cinacalcet for treating secondary hyperparathyroidism in people with kidney disease who are on dialysis. January 2007. Available at: http://www.nice.org.uk/nicemedia/pdf/ TA117publicinfo.pdf.
23. R. Narayan, R.M. Perkins, E.P. Berbano, C.M. Yuan, R.T. Neff, and E.S. Sawyers Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis Am J Kidney Dis 49 2007 801 813
24. R. Garside, M. Pitt, R. Anderson, S. Mealing, R. D'Souza, and K. Stein The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective Nephrol Dial Transplant 22 2007 1428 1436